Fatal Autoimmune Hemolytic Anemia Associated with Alemtuzumab in a MS Patient with Severe Relapsing Remitting Disease Course and Prior Immune Therapies (P2.103)

CONCLUSIONS: This case of fatal autoimmune hemolytic anemia associated with alemtuzumab treatment adds further evidence to the potential risk of antibody mediated side effects and argues for close hematological monitoring of patients.Disclosure: Dr. Rieckmann has received personal compensation for activities with Bayer, Biogen Idec, Boehringer Ingelheim, Novartis, Merck-Serono, Teva, and Genzyme. Dr. Lenz has nothing to disclose. Dr. Hoffmann has nothing to disclose. Dr. Poske has nothing to disclose. Dr. Behr has nothing to disclose. Dr. Kallmann has received honoraria for serving on advisory boards and as speaker from Merck Serono, Biogen-Idec, Sanofi/Genzyme, Teva and Novartis.
Source: Neurology - Category: Neurology Authors: Tags: MS and CNS Inflammatory Disease: Treatment, Safety, and Tolerance Source Type: research

Related Links:

Authors: Rombauts A, Abelenda-Alonso G, Cuervo G, Gudiol C, Carratalà J Abstract INTRODUCTION: Despite adequate antibiotic coverage, community-acquired pneumonia (CAP) remains a leading cause of hospitalization and mortality worldwide. It induces both a local pulmonary and a systemic inflammatory response, particularly significant in severe cases. The intensity of the dysregulated host response varies from patient to patient and has a negative impact on survival and other outcomes. AREAS COVERED: This comprehensive review summarizes the pathophysiological aspects of the inflammatory response in CAP, brie...
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
We describe the most highly recommended generic and disease-specific PRO tools in SCD and discuss the challenges of incorporating them in clinical practice. EXPERT OPINION: PRO measures are essential to incorporate into SCD clinical trials either as primary or secondary outcomes. The use of PRO measures in SCD facilitates a patient-centered approach, which is likely to lead to improved outcomes. Significant challenges remain in adapting PRO tools to routine clinical use and in developing countries. PMID: 33034214 [PubMed - as supplied by publisher]
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Publication date: Available online 9 October 2020Source: Mutation Research/Reviews in Mutation ResearchAuthor(s): Klaudia Kulczynska-Figurny, James J. Bieker, Miroslawa Siatecka
Source: Mutation Research Reviews in Mutation Research - Category: Genetics & Stem Cells Source Type: research
Currently in fellowship doing bread/butter procedures (MBB, epidurals, PNB, few SCS/PNS trials, etc.) and just interviewed at a private practice spot where they do a lot of procedures that I will have not done any training in prior to graduating (e.g. IT pump, SI fusion, Vertiflex, Kypho, MILD, Discectomy, lots of SCS/PNS trials etc) and significant amount of "OR pain procedures" at a very busy practice seeing 30-40 pts/day - how many of you are commonly performing these procedures and are... private practice concern
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Pain Medicine Source Type: forums
Publication date: Available online 9 October 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Brenda Bertado-Cortés, Claudia Venzor-Mendoza, Daniel Rubio-Ordoñez, José Renán Pérez-Pérez, Lucy Andrea Novelo-Manzano, Lyda Viviana Villamil-Osorio, María de Jesús Jiménez-Ortega, María de la Luz Villalpando-Gueich, Nayeli Alejandra Sánchez-Rosales, Verónica García-Talavera
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: October 2020Source: Brain, Behavior, and Immunity, Volume 89Author(s): Fernando Lopes, Fernando A. Vicentini, Nina L. Cluny, Alexander J. Mathews, Benjamin H. Lee, Wagdi A. Almishri, Lateece Griffin, William Gonçalves, Vanessa Pinho, Derek M. McKay, Simon A. Hirota, Mark G. Swain, Quentin J. Pittman, Keith A. Sharkey
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
BEST supplements to relieve joint pain: Is your arthritis playing up? The wetter and colder months could partially be to blame. These two pills may help.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Kim H, Lim YM, Lee EJ, Kim HW, Ahn HS, Kim KK PMID: 33029979 [PubMed]
Source: Journal of Clinical Neurology - Category: Neurology Tags: J Clin Neurol Source Type: research
CONCLUSIONS: Tacrolimus may be a safe and effective immunosuppressant for refractory or relapsing form of orbital or cranial IIPs. PMID: 33029975 [PubMed]
Source: Journal of Clinical Neurology - Category: Neurology Tags: J Clin Neurol Source Type: research
More News: Anemia | Autoimmune Disease | Bilirubin | Blood Transusion | Brain | Cardiology | Corticosteroid Therapy | Gilenya | Heart | Hematology | Hospital Management | Jaundice | Merck | Microbiology | Multiple Sclerosis | Neurology | Pain | Pain Management | Pathology | Respiratory Medicine | Septic Shock | Tysabri